MEMANT-3310 is under clinical development by Antabio and currently in Phase I for Acinetobacter Infections. According to GlobalData, Phase I drugs for Acinetobacter Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MEMANT-3310 LoA Report. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MEMANT-3310 overview

MEMANT-3310 is under development for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections and hospital acquired infections caused by Gram negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant A. baumannii (CRAB). It is a combination of meropenem and ANT-3310. It is administered through intravenous route. ANT-3310 acts by targeting serine beta-lactamases and meropenem acts by targeting penicillin binding protein (PBP).

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Antabio overview

Antabio is a biopharmaceutical company. It develops novel antibacterials targeting drug-resistant pathogens. The company’s pipeline products comprise MEM-ANT3310

For a complete picture of MEMANT-3310’s drug-specific PTSR and LoA scores, buy the report here.